COMBINATION OF BEVACIZUMAB, IRINOTECAN AND TEMOZOLOMIDE FOR RELAPSED OR REFRACTORY NEUROBLASTOMA: A PHASE II STUDY.

Trial Profile

COMBINATION OF BEVACIZUMAB, IRINOTECAN AND TEMOZOLOMIDE FOR RELAPSED OR REFRACTORY NEUROBLASTOMA: A PHASE II STUDY.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 17 May 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Irinotecan (Primary) ; Temozolomide (Primary)
  • Indications Neuroblastoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 May 2017 Planned End Date changed from 1 Apr 2017 to 1 Apr 2018.
    • 10 May 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Apr 2018.
    • 07 Jun 2016 Results (n=33) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top